Int J Biol Sci 2020; 16(1):162-171. doi:10.7150/ijbs.36429

Research Paper

A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation

Yue Cui1*, Chunxiao Lu1*, Zhiming Zhang2, Aiqin Mao1, Lei Feng1, Li Fu3✉, Feng Gu3✉, Xin Ma1✉, Dongxu He2✉

1. Wuxi School of Medicine, Jiangnan University, Wuxi, China.
2. School of Food Science and Technology, Jiangnan University, Wuxi, China.
3. Department of Breast Cancer Pathology and Research Laboratory, State Key Laboratory of Breast Cancer Research, Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
* These authors contributed equally to this study

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Cui Y, Lu C, Zhang Z, Mao A, Feng L, Fu L, Gu F, Ma X, He D. A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation. Int J Biol Sci 2020; 16(1):162-171. doi:10.7150/ijbs.36429. Available from http://www.ijbs.com/v16p0162.htm

File import instruction

Abstract

Great quantity of intergenic noncoding RNAs (lncRNAs) have been identified in the mammalian genome and involved in various biological processes, especially in the development and metastasis of cancer. In this study, we identified one lncRNA, lncRNA NONHSAT028712 (Lnc712), was highly expressed in breast cancer cell lines and tissues based on microarray screening. Knockdown of Lnc712 largely inhibited breast cancer cell proliferation. Mechanistically, Lnc712 bound specifically to heat-shock protein 90 (HSP90). Interaction between Lnc712 and HSP90 is required for HSP90 binding to cell division cycle 37 (Cdc37). The Lnc712/HSP90/Cdc37 complex regulated cyclin-dependent kinase 2 (CDK2) activation and then triggered breast cancer cell proliferation. In summary, our results identified a new lncRNA regulate breast cancer proliferation though interaction with HSP90.

Keywords: Long non-coding RNAs, Breast Cancer, HSP90, CDK2